# Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

> **NCT05778071** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 165 (estimated)

## Conditions studied

- Chronic Hypoparathyroidism
- Endocrine System Diseases
- Parathyroid Diseases

## Interventions

- **COMBINATION_PRODUCT:** eneboparatide
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT05778071
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-07
- **Primary completion:** 2024-11-15
- **Final completion:** 2027-06-16
- **Target enrollment:** 165 (ESTIMATED)
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05778071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05778071, "Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05778071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*